This is the first DPP-4 inhibitor to be approved in a single dose, without the need to adjust the dose in type-2-diabetes patients with renal or hepatic deterioration.
The fourth edition of this program promoted by “la Caixa”, Barcelona Activa, Biocat, Genoma España and the Barcelona Chamber of Commerce was presented this morning.
Afterwards, a proactive public purchasing policy linked to the most innovative Catalan biotech companies will be presented to the Government of Catalonia.
Winter has 20 years of experience in the biotech sector and in international venture capital at companies like ERA Biotech, Sofinnova Partners and Furman Selz, Inc.
It is the first company to be installed in the Parc Científic i Tecnològic de Terrassa. Its general manager, Marc Canales, says that "we are convinced that we can create a cluster of leading companies and create synergies".
Companies are eligible for the BioEmprenedorXXI award, which includes training, incubation, internationalization and funding actions to start up a business project.
